Key Takeaways
- Organization design should begin with the market, not an inherited template.
- Senior commercial leadership is often needed before large-scale commercial hiring begins.
- Build-versus-outsource decisions should reflect strategic importance, capability and continuity.
- Hiring too early wastes capital; hiring too late creates execution risk.
- Commercial functions should grow according to evidence, milestones and market requirements.
Building a biotechnology company's first commercial organization is fundamentally different from expanding an established pharmaceutical business.
There is no existing infrastructure to inherit.
Leadership must determine what capabilities are required, when they are needed, which should remain internal, what can be outsourced and how the organization should evolve as uncertainty declines.
The objective is not to recreate a large pharmaceutical company on a smaller scale.
It is to build the organization the therapy actually requires.
Start With the Therapy and the Market
Organization design should follow commercial reality.
A therapy prescribed by a small number of highly specialized physicians may require a concentrated, experienced field organization. A product involving complex reimbursement may require significant Market Access and patient-support capability. A rare disease program may place greater emphasis on patient identification, referral networks and Centers of Excellence. A hospital-administered product may create different institutional and reimbursement requirements.
There is no universally correct biotechnology commercial organization.
The correct design depends upon patient population, physician concentration, treatment setting, access complexity, distribution, patient services, competitive intensity, launch geography, company strategy and capital.
Commercial Leadership Comes Before Commercial Scale
The first major commercial hire is often more consequential than the eventual size of the sales organization.
Early commercial leadership may need to define the commercial strategy, challenge market assumptions, participate in development decisions, build the organizational roadmap, establish priorities, recruit functional leaders, communicate with the board, align Medical Affairs and Market Access, determine what should be outsourced and build launch governance.
This role requires enterprise perspective.
The first commercial leader should not simply be selected because they have managed a large sales or marketing organization elsewhere.
Building from zero requires a different capability from operating an established system.
Build in Sequence
Commercial organizations should be built according to decision requirements rather than simultaneously.
An illustrative sequence may include:
Strategic Commercial Leadership
Introduced when important commercialization decisions require experienced commercial judgment.
Market and Customer Insight
Develop market understanding, patient journeys, physician segmentation and competitive intelligence.
Market Access
Introduce access expertise early enough to influence evidence, reimbursement planning and infrastructure.
Commercial Operations
Develop forecasting, analytics, systems, incentive planning, territory design and operational processes as requirements become clearer.
Marketing
Translate market understanding and product strategy into positioning, segmentation, communication and launch planning.
Patient Services
Build according to disease, treatment, reimbursement and support requirements.
Field Organization
Recruit and deploy only after the company understands whom it needs to reach, why, where and with what model.
The exact sequence will vary.
The principle is that each capability should arrive before it becomes a critical dependency.
Build Versus Outsource
Emerging biotechnology companies do not need to own every capability.
Specialist partners can provide scale, expertise and flexibility.
But outsourcing should not become a substitute for internal accountability.
Capabilities More Likely to Require Internal Ownership
Depending on the company, these may include commercial strategy, senior leadership, key market knowledge, critical stakeholder relationships, strategic decision-making and organizational accountability.
Capabilities That May Be Outsourced or Hybrid
Depending on requirements: market research, analytics, selected operations, training support, specialized access work, technology, certain field capabilities and communications support.
The correct question is not: “Can we outsource this?”
The better question is: “Where must the company retain knowledge, control and continuity?”
Avoid Building the Large-Pharma Organization Too Early
Executives joining emerging biotechnology companies often bring valuable experience from larger organizations.
The risk is importing the structure of those organizations without examining why the structure existed.
Large pharmaceutical companies may have multiple management layers, large functional teams, established systems, broad portfolios, mature operations and significant support infrastructure.
A first-launch biotechnology company operates under very different constraints.
Every role should have a clear reason to exist.
The organization should be designed around the asset, the market and the stage of development.
Avoid Hiring Too Late
The opposite mistake is equally serious.
Companies sometimes postpone commercial hiring until approval appears close because they want to conserve capital.
This can create hidden costs.
Important commercial decisions may already have been made without appropriate expertise. Evidence gaps may be difficult to address. Technology and operational systems may require more time than expected. Leadership recruitment itself can take months. The commercial model may still be unresolved.
Delaying headcount is financially prudent when capability is not yet needed.
Delaying commercial judgment is different.
Cross-Functional Design Matters
The commercial organization cannot be designed in isolation.
Successful launch preparation requires coordination across Clinical Development, Regulatory, Medical Affairs, Market Access, Finance, Legal and Compliance, Supply Chain, Patient Services, Commercial Operations and executive leadership.
Each function maintains distinct responsibilities.
But the organization must operate from a shared understanding of the market and the company's objectives.
Culture Begins Before the Organization Is Large
Commercial culture is often discussed as though it becomes relevant once hundreds of employees have been hired.
In reality, culture begins with the first leadership decisions.
What behaviors are rewarded? How are disagreements handled? Who owns decisions? How quickly does the organization act? Are functions aligned around the same goals? Does leadership distinguish accountability from bureaucracy?
Early leadership choices can become operating habits that are difficult to change later.
A Better Question Than “How Many People Do We Need?”
The most useful organization-design question is not initially headcount.
It is capability.
Ask: What decisions must the company make? What work must the company perform? What capabilities are required? When are those capabilities needed? Which must exist internally? Which can be accessed externally? Who is accountable? What depends on what?
Headcount follows those answers.
Conclusion
The first commercial organization should be built deliberately.
Too much infrastructure too early consumes capital and may create complexity before the strategy is clear.
Too little capability too late creates commercial risk precisely when the organization has the fewest options.
The strongest approach is staged development.
Understand the market. Define the capabilities. Establish leadership. Sequence investment. Build what the therapy requires.
That creates an organization designed to commercialize the product rather than one designed to resemble someone else's company.
Building Your First Commercial Organization?
PharmaKonsult helps biotechnology leadership teams evaluate commercial leadership, organizational design, capability requirements and launch readiness.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
